What is Geron's latest dividend and current dividend yield?

What is the market's earnings forecast for Geron next quarter?

What were the key takeaways from Geron's earnings call?

What is Geron's gross profit margin?

What is the revenue and EPS growth rate for Geron year over year?

Did Geron beat or miss consensus estimates last quarter?

What were the key takeaways from Geron’s earnings call?

What does Geron do and what are its main business segments?

- **Revenue decline**: Q3 net product revenue down 3% YoY due to later-line patient attrition
- **Strategic focus**: Shifting to first-line patients with >500 EPO, expanded community engagement
- **Clinical momentum**: Phase III myelofibrosis trial fully enrolled (320 pts), interim analysis H2 2026
- **Financial stability**: $420M cash, 2025 OpEx guidance $250-260M
- **Global expansion**: EU named patient program active, exploring 2026 commercialization
- **Execution priority**: Educating HCPs on RYTELO as second-line therapy, not last resort

**【CEO Summary Section】**
- Q3 net product revenue: $47.2 million, down 3% YoY due to discontinuations in later-line patients.
- New patient starts in first/second-line increased to 36% (vs. 30% Q2), but offset by higher discontinuations.
- 150 new ordering accounts added, expanding prescriber base to 1,150.
- First shipment of RYTELO to Germany under named patient program; preparing for EU commercial launch in 2026.
- Strategic priorities: 
  - Increase HCP education on RYTELO as second-line therapy
  - Expand community site penetration
  - Initiate investigator-sponsored trials (ISTs) in U.S.
  - Engage at ASH 2025 with 5 abstracts highlighting long-term efficacy

**【CFO Financial Commentary】**
- Cash balance: $420 million (vs. $503 million at year-end 2024)
- Q3 2025 net revenue: $47 million (vs. $28 million Q3 2024)
- Gross to net rate increased due to:
  - Higher Medicaid rebate reserves
  - Returns from expiring inventory
  - New GPO contract fees
- R&D expenses: $21 million (flat vs. Q3 2024)
- SG&A expenses: $39 million (up 8% vs. Q3 2024) due to salesforce expansion
- 2025 OpEx guidance: $250-260 million (down from prior $270-285 million range)

**【Q&A Key Highlights】**
- **Gross to net trends**: Mid-teen range still applicable; one-time adjustments for Medicaid mix and returns
- **Demand drivers**: 
  - 80% of patients are later-line (shorter duration)
  - Focus on first-line patients with >500 EPO
  - ASH 2025 engagement shows shifting perception of RYTELO as second-line option
- **Salesforce effectiveness**: 
  - Field force fully hired and trained
  - Doubling MSLs to support medical affairs
  - Metrics: Reorder rate 80%, 36% new patient starts
- **EU partnership**: 
  - Named patient program in Germany
  - Exploring strategic partnerships for 2026 launch
  - No timeline for direct EU commercialization
- **Growth timeline**: 2026 growth story; no specific quarterly guidance

Geron Corporation (GERN) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

GERN

GERN fundamentals

You can ask Aime